Sage Therapeutics Company Profile (NASDAQ:SAGE)

Analyst Ratings

Consensus Ratings for Sage Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 1 Sell Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $69.20 (56.10% upside)

Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016William BlairReiterated RatingOutperform$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016JPMorgan Chase & Co.Reiterated RatingBuy$71.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Chardan CapitalReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016BMO Capital MarketsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Leerink SwannReiterated RatingBuy$66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016HC WainwrightInitiated CoverageBuy$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Goldman Sachs Group Inc.Reiterated RatingBuy$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015SunTrust Banks Inc.Initiated CoverageBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Sage Therapeutics (NASDAQ:SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.99)($0.91)($0.95)
Q2 20164($1.12)($0.94)($1.03)
Q3 20164($1.22)($0.98)($1.09)
Q4 20164($1.29)($1.00)($1.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sage Therapeutics (NASDAQ:SAGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sage Therapeutics (NASDAQ:SAGE)
DateHeadline
07/25/16 08:14 AMImportance Of Phase 2 Trials -
07/22/16 06:02 PMForm 8-K Sage Therapeutics, Inc. For: Jul 15 - StreetInsider.com
07/22/16 06:02 PMSage Therapeutics Incorporated (NASDAQ:SAGE) Sellers Increased By 20.32% Their Shorts - Consumer Eagle
07/22/16 06:02 PMWhat's Next for SAGE Therapeutics Inc After Today's Huge Increase? - Consumer Eagle
07/22/16 02:18 PMEdited Transcript of SAGE earnings conference call or presentation 5-May-16 8:30pm GMT -
07/21/16 03:11 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem -
07/21/16 09:04 AMEarnings Focus and Crowd Sourced Sentiment Review for Sage Therapeutics, Inc. (NASDAQ:SAGE) - TGP
07/20/16 07:06 PMSage Therapeutics, Inc. (NASDAQ:SAGE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 07:06 PMSolid Performer in Focus: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily
07/19/16 06:00 AMSage Appoints Geno Germano to Company's Board of Directors - [Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage’s Board of Directors.
07/18/16 11:50 AMTrading Performance and Target Watch for Sage Therapeutics, Inc. (NASDAQ:SAGE) - Press Telegraph
07/18/16 11:50 AMStock in Positive Territory for the Quarter: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily
07/18/16 11:50 AMShares of Sage Therapeutics (SAGE) Rally 24.29% - Trade Calls
07/13/16 06:40 PMDid SAGE Therapeutics Inc (NASDAQ:SAGE) Just Cure Depression?
07/13/16 03:58 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/13/16 09:07 AMRatings Analysis of: Sage Therapeutics, Inc. (NASDAQ:SAGE) - News Oracle
07/13/16 09:07 AMJP Morgan Reiterates Overweight on SAGE Therapeutics Inc (SAGE) Following Positive Top-Line Phase 2 Data - Smarter Analyst
07/13/16 09:07 AMBuzz Stocks: Alcoa Inc, Fastenal Company, and SAGE Therapeutics Inc - Schaeffers Research (blog)
07/13/16 09:07 AMSage Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/13/16 08:26 AMCoverage of Top Gainers SAGE Therapeutics, Seagate Technology, and Cascadian Therapeutics -
07/12/16 06:29 PMHere's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today
07/12/16 05:14 PMAfter-hours buzz: JUNO, TEVA, SAGE & more -
07/12/16 04:19 PMSage Therapeutics shares soar on positive postpartum depression drug results -
07/12/16 03:31 PMSage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results -
07/12/16 10:39 AMSage's Phase 2 Clinical Trial Of SAGE-547 Achieves Primary Endpoint In Severe Postpartum Depression
07/12/16 10:39 AMSage Surges After Postpartum Drug Meets Goals in Trial
07/12/16 10:39 AMSage's drug for postpartum depression succeeds in mid-stage study
07/12/16 10:39 AMSage Therapeutics (SAGE) Boosted by Promising Postpartum Depression Drug Data
07/12/16 10:39 AMBuzz Stocks: Alcoa Inc, Fastenal Company, and SAGE Therapeutics Inc
07/12/16 10:39 AMStocks to Watch: Starbucks, Sage Therapeutics, Seagate Technology
07/12/16 10:39 AMSage Therapeutics' postpartum depression drug succeeds in study
07/12/16 10:27 AMSage Therapeutics: That's Some Data! -
07/12/16 09:39 AMSage Therapeutics Inc: SAGE Stock Jumps 40% on Phase-2 PPD Results - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Sage Therapeutics Inc (SAGE) may find itself as the one and only serious player in this niche sliver of the depression market. The post Sage Therapeutics Inc: SAGE Stock Jumps 40% on Phase-2 PPD Results appeared first on InvestorPlace.
07/09/16 05:36 PMWere Analysts Bullish SAGE Therapeutics Inc (NASDAQ:SAGE) This Week? - Engelwood Daily
07/08/16 06:14 PMSage Therapeutics, Inc. Stock Momentum at Critical Inflection Point - CML News
07/07/16 06:18 PMEssential Tremor Pipeline Review 2016 Featuring Merz GmbH & Co., Neurocrine Biosciences & Sage Therapeutics - Research and Markets
07/07/16 09:02 AMStock Tracking Down This Month; Investor Alert on Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily
07/07/16 09:02 AMInsiders are Gradually Selling Sage Therapeutics, Inc. (NASDAQ:SAGE) - Telanagana Press
07/07/16 09:02 AMBMO Capital Initiates Coverage on SAGE Therapeutics Inc to Outperform - TheFounders Daily
07/05/16 10:42 AMBroker Outlook For The Week Ahead Sage Therapeutics, Inc. (SAGE) - Fiscal Standard
07/02/16 05:49 PMHow Analysts Feel About SAGE Therapeutics Inc (NASDAQ:SAGE)? - Press Telegraph
07/01/16 02:20 PMBiotech catalysts -
06/30/16 06:29 PMH.C. Wainwright Initiates Coverage on SAGE Therapeutics Inc to Buy - Trade Calls
06/30/16 09:03 AMIs Sage Therapeutics (NASDAQ:SAGE) Worth Your Time? BMO Capital Thinks So - Press Telegraph
06/28/16 06:08 PMOption Market: Sage Therapeutics Inc. Risk Hits An Extreme High - CML News
06/28/16 11:03 AMSAGE Therapeutics : Why Investors Have These Biotech Stocks on Their Radar? - Cerus, Juno Therapeutics, Chiasma, and Sage Therapeutics
06/27/16 10:25 AMHot Stock List: Sage Therapeutics, Inc. (NASDAQ:SAGE), Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL ... - KC Register
06/27/16 10:25 AMNext Weeks Broker Price Targets For Sage Therapeutics, Inc. (SAGE) - Fiscal Standard
06/25/16 09:59 AMSage Therapeutics (NASDAQ:SAGE) stock price target bumped up to $56 as recorded today by H.C. Wainwright
06/24/16 09:01 AMBulls see upside in Sage Therapeutics -

Social

About Sage Therapeutics

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company's lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SAGE
  • CUSIP:
Key Metrics:
  • Previous Close: $44.33
  • 50 Day Moving Average: $34.18
  • 200 Day Moving Average: $34.31
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.42B
  • Beta: 2.35
  • Current Year EPS Consensus Estimate: $-4.30 EPS
  • Next Year EPS Consensus Estimate: $-4.62 EPS
Additional Links:
Sage Therapeutics (NASDAQ:SAGE) Chart for Tuesday, July, 26, 2016